The Malaria Rapid Diagnostic Devices Market report evaluates key variables driving the growth of the industry and identifies key challenges, opportunities, and regional markets. The study highlights the global market for this device, which is expected to grow at a CAGR of over 5% during the forecast period. The market is highly fragmented, but major players in the industry are strengthening their product portfolios and expanding their geographic presence to increase their share.
Leading companies in the malaria rapid diagnostic devices market include Abbott Laboratories, Atomo Diagnostics, Bio-Rad Laboratories Inc., Drucker Diagnostics, and ERADA Technology Alliance. In addition to these players, companies such as Omega Diagnosis Group Plc., QIAGEN N.V., and SD Biosensor Inc. are driving the industry. These companies have invested heavily in malaria rapid diagnostics technology.
Moreover, the growth of the market for malaria rapid diagnostics devices is projected to increase over the next five years. The COVID-19 coronavirus outbreak has spread across almost every country in the world Health Organization has declared it a public health emergency. The impacts are already beginning to be felt, and the market for malaria rapid diagnostic devices will witness rapid growth. Other factors driving the market include the increasing need for accurate diagnostics, technological advancement, and increased investment.
The growth of the Malaria rapid diagnostic devices market is primarily driven by the government's support and the increasing incidence of malaria disease. The growing number of patients in low-income regions and the development of new diagnostic methods is one of the major factors driving the market for these diagnostics. Besides the rising prevalence of malaria in the developing world, the rapid diagnosis methods have also become more accessible and cost-effective. A good device that can quickly diagnose the disease can save lives.
The malaria rapid diagnostic devices market is largely driven by the increasing incidence of malaria. The prevalence of malaria has been increasing across the world for the past decade, and the need for malaria rapid diagnostic test has helped prevent the disease. The growth of the malaria rapid diagnostic devices market is anticipated to continue at a healthy pace over the next five years. Several leading players are in the market for these diagnostic devices, and have a large share of the overall market.
The region with the highest CAGR over the forecast period is Asia-Pacific. The Asia-Pacific region is expected to grow at the fastest CAGR during the forecast period. The fast growth is attributed to the increasing awareness of malaria diagnostics. They allow patients to get the right treatment at the right time, and thus are a major part of the market in developing countries. There is also a steady growth in the Middle East and North America.
The World Health Organization recommends the use of a rapid malaria test (RDT) for diagnosis. The RDT is not only more sensitive and specific than microscopy, but it also saves time and costs. Although this method is time-consuming and labor-intensive, it has become the gold standard for diagnosing malaria and extending the lives of patients. The cost of a RDT is often prohibitive for health workers, especially in remote areas.
A RDT for malaria uses immunochromatographic technology to detect parasite antigens in a patient's blood. The RDT migrates the liquid across a nitrocellulose membrane, detecting plasmodial antigens. The method utilizes two sets of antibodies, one monoclonal and the other polyclonal. These antibodies are relatively specific, but the performance characteristics of the rapid malaria test depend on their source of antigen.
Rapid diagnostic tests use lateral flow immunochromatographic technology to detect malaria antigens. The antibodies migrate across a nitrocellulose membrane, where they react with the antigen. There are two types of antigens, one monoclonal and the other polyclonal. The monoclonal antibodies are generally more sensitive, while the polyclonal antibody is less specific. Both types of antibody are effective in detecting malaria, but there are some differences.
There are several different rapid malaria tests available. Paracheck TM-Pf, manufactured by Hangzhou Biotest Biotech Co, China, is a rapid test that detects the malaria antigen in human blood. The kit's sensitivity varies depending on the antigen used and the source of the antigen. For example, a monoclonal antibody can be very sensitive and specific, whereas a polyclonal antibody has lower sensitivity.
The two major types of malaria RDTs are based on lateral flow immunochromatographic technology, which uses liquid to migrate the antigen in the form of a gel. The test is more sensitive than a traditional blood-based test and detects P. falciparum at 125 parasites per microliter of blood. It also costs less than a dollar a chip, which makes it extremely affordable for point-of-care field testing.
A new rapid malaria test developed by researchers at the Nanyang Technological University of Singapore is expected to provide results in as little as 30 minutes. It is intended to simplify malaria diagnosis and can be used in the field. Its accuracy is 100 times greater than commercially available tests, which are difficult to measure with microfluidics. In addition, the test is inexpensive. Despite its high sensitivity, the rapid malaria test cannot detect the cause of the infection. It is only accurate in malaria-infected people.
A rapid malaria test is not a substitute for a blood smear. A blood smear provides the only certainty for a correct diagnosis. A RDT may be the only way to tell if you have malaria. A negative result means that you have no malaria. But it can also help to determine if you are getting a malaria infection. The RDT does not have the same sensitivity as a normal test, and the results will not be the same.